GLP-1s: Wonder Drugs or Wall Street Worries?

Are Ozempic and Wegovy wonder drugs or financial burdens? Despite their weight loss and diabetes benefits, GLP-1 drug stocks are surprisingly down. We explore the price vs. value debate, insurance coverage hurdles, and potential game-changers like new cost-effectiveness data and direct-to-consumer options that could reshape the future for patients and pharma companies alike. Hosted on Acast. See acast.com/privacy for more information.